Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Chemotherapy + Aspirin in ES-SCLC
NCT06554535Phase 2Not yet recruiting
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors, Orthosteric Ligands
01
Overview
A Phase 2 trial of serplulimab, aspirin in small cell lung cancer (SCLC). Planned start Oct 2024; status: not yet recruiting.
02
Drugs
serplulimabaspirin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06554535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554535.